Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Dipyridyl. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 known ✓ | P51681 | 3/20 | 0.93 |
| ▸ | HSP90AA1 known ✓ | P07900 | 1/20 | 0.74 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.62 |
| ▸ | CYP19A1 known ✓ | P11511 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.93 |
| ▸ | LMNA | P02545 | 3/20 | 0.93 |
| ▸ | CCR1 | P32246 | 3/20 | 0.93 |
| ▸ | CCR8 | P51685 | 3/20 | 0.93 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.93 |
| ▸ | POLB | P06746 | 1/20 | 0.93 |
| ▸ | METAP1 | P53582 | 1/20 | 0.93 |
| ▸ | BLM | P54132 | 1/20 | 0.93 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.93 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.93 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.93 |
| ▸ | NPC1 | O15118 | 6/20 | 0.74 |
| ▸ | TP53 | P04637 | 4/20 | 0.74 |
| ▸ | RAB9A | P51151 | 4/20 | 0.74 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dipyridyl SCHEMBL30443629 | 1.00 | KDM4E (0.93) | KDM4ELMNACCR1CCR5CCR8 | |
| Dipyridyl SCHEMBL28365105 | 1.00 | KDM4E (0.93) | KDM4ELMNACCR1CCR5CCR8 | |
| Dipyridyl SCHEMBL501755 | 1.00 | KDM4E (0.93) | KDM4ELMNACCR1CCR5CCR8 | |
| Dipyridyl SCHEMBL29064174 | 1.00 | KDM4E (0.93) | KDM4ELMNACCR1CCR5CCR8 | |
| Dipyridyl SCHEMBL31480063 | 1.00 | KDM4E (0.93) | KDM4ELMNACCR1CCR5CCR8 | |
| Dipyridyl SCHEMBL4263105 | 1.00 | KDM4E (0.93) | KDM4ELMNACCR1CCR5CCR8 | |
| Dipyridyl SCHEMBL4220617 | 1.00 | KDM4E (0.93) | KDM4ELMNACCR1CCR5CCR8 | |
| Dipyridyl SCHEMBL10395611 | 1.00 | KDM4E (0.93) | KDM4ELMNACCR1CCR5CCR8 | |
| Dipyridyl SCHEMBL1450622 | 1.00 | KDM4E (0.93) | KDM4ELMNACCR1CCR5CCR8 | |
| Dipyridyl SCHEMBL30008960 | 1.00 | KDM4E (0.93) | KDM4ELMNACCR1CCR5CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5534132-A | Electrode and method for the detection of an affinity reaction | VREEKE MARK (US) | 1996-07-09 | — | — | US | claimed |
| CN-118108753-A | N, N-dialkyl thioformyl-containing 2-silicon-based indole or pyrrole compound and synthesis method and application thereof | 杭州师范大学 | 2024-05-31 | — | — | CN | disclosed |
| CN-116970020-B | Abiraterone compound preparation method | 天津凯莱英制药有限公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-116970020-A | Abiraterone compound preparation method | 天津凯莱英制药有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116332739-A | Preparation method and application of ring belt arene and derivative | 清华大学 | 2023-06-27 | — | — | CN | disclosed |
| CN-116284147-A | Fluorescent probe for selectively detecting hNQO1 with high expression in tumor cells and application thereof | 青岛大学 | 2023-06-23 | — | — | CN | disclosed |
| CN-114341621-A | Method for detecting an analyte | PSYROS诊断有限公司 | 2022-04-12 | — | — | CN | disclosed |
| US-10806694-B2 | Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof | THE UNIVERSITY OF CHICAGO (US) | 2020-10-20 | — | — | US | disclosed |
| US-10780045-B2 | Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, chemotherapy, immunotherapy, and any combination thereof | THE UNIVERSITY OF CHICAGO (US) | 2020-09-22 | — | — | US | disclosed |
| EP-3206987-B1 | NANOPARTICLES FOR PHOTODYNAMIC THERAPY, X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION THEREOF | UNIV CHICAGO (US) | 2020-07-01 | — | — | EP | disclosed |
| US-20030225298-A1 | Method of preparing amino carboxylic acids | MONSANTO TECHNOLOGY LLC | 2003-12-04 | — | — | US | disclosed |
| EP-0973719-A4 | METHOD OF PREPARING AMINO CARBOXYLIC ACIDS | MONSANTO CO (US) | 2000-05-17 | — | — | EP | disclosed |
| EP-0973719-A1 | METHOD OF PREPARING AMINO CARBOXYLIC ACIDS | MONSANTO COMPANY (US) | 2000-01-26 | — | — | EP | disclosed |
| US-5811526-A | LUMINESCENT IRIDIUM COMPLEXES, E.G. IR(BIPY)2(4'-(1,10-PHENANTHROLINE))-PHENOXYACETIC ACID)(3+),FOR IMMUNOASSAY; STABILITY; LONG LIFE; NONTOXIC | ALUSUISSE HOLDINGS A.G. (CH) | 1998-09-22 | — | — | US | disclosed |
| WO-1998035930-A1 | METHOD OF PREPARING AMINO CARBOXYLIC ACIDS | MONSANTO COMPANY (US) | 1998-08-20 | — | — | WO | disclosed |
| EP-0757246-A2 | Conducting paste, electrodes, sensors and electrochemical reactors containing said paste, and their manufacturing method | Universitat Rovira I Virgili - Servei de Tecnologia Quimica (ES) | 1997-02-05 | — | — | EP | disclosed |
| US-5585279-A | IMMUNOASSAYS | LONZA GROUP, AG (CH) | 1996-12-17 | — | — | US | disclosed |
| EP-0255534-B1 | BINDING ASSAY AND ASSAY REAGENT | CELLTECH LIMITED (GB) | 1992-04-08 | — | — | EP | disclosed |
| EP-0255534-A1 | BINDING ASSAY AND ASSAY REAGENT. | DAVIDSON ROBERT STEPHEN | 1988-02-10 | — | — | EP | disclosed |
| WO-1987004523-A1 | BINDING ASSAY AND ASSAY REAGENT | DAVIDSON ROBERT STEPHEN | 1987-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10780045-B2 | Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, chemotherapy, immunotherapy, and any combination thereof | CD274, PDCD1, PDCD1LG2 | CCR5 1961/4885HSP90AA1 1662/4885GLA 1303/4885 |
| US-10806694-B2 | Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof | CD274, PDCD1, PDCD1LG2 | CCR5 2046/4885HSP90AA1 864/4885GLA 1918/4885 |
| US-20030225298-A1 | Method of preparing amino carboxylic acids | CPS1, GNMT, HNMT | CCR5 3922/4885HSP90AA1 2945/4885GLA 2355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.